Anagnostou 2018.

Methods	12‐week trial of tideglusib versus placebo
Participants	Inclusion criteria: not specified apart from aged 12‐18 years Exclusion criteria: details not provided (conference poster) Location/setting: not specified but assumed to be either the USA or Canada Number of participants randomly assigned: not specified apart from 83 were randomised in a 1:1 manner Number of withdrawals/dropouts: not reported Gender: not reported Mean age: not reported IQ: not reported Concomitant medications: not reported History of previous medications: not reported
Interventions	Intervention (tideglusib): once‐daily oral administration of tideglusib commenced at 400 mg increasing to 1000 mg (1g) Comparator (placebo): not described Timing of outcome assessments: baseline and 12 weeks (endpoint)
Outcomes	Primary outcomes: AEs Repetitive Behaviour Scale‐Revised (not clear which subscales/outcomes measured)
Notes	Study start date: not reported Study end date: not reported Funding: not reported Conflicts of interest: not reported